AbbVie Inc.

More coverage

AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'

Earnings 1 d ago

BofA raises Abbvie stock price target on Apogee deal close

Markets 16 d ago

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

Markets 20 d ago

AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)

Markets 20 d ago

ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?

Markets 21 d ago

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Markets 26 d ago also on JNJ

Has AbbVie Stock Become Too Expensive to Buy?

Markets 29 d ago

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.

Markets 31 d ago

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

Markets 31 d ago

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year

Markets 39 d ago

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

Policy 41 d ago also on GMAB

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

Markets 42 d ago